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Abstract
Loss of barrier integrity precedes the development of pathologies such as metastasis, inflammatory disorders, and blood-
retinal barrier breakdown present in neovascular age-related macular degeneration. Rap1 GTPase is involved in regulating
both endothelial and epithelial cell junctions; the specific role of Rap1A vs. Rap1B isoforms is less clear. Compromise of
retinal pigment epithelium barrier function is a contributing factor to the development of AMD. We utilized shRNA of Rap1
isoforms in cultured human retinal pigment epithelial cells, along with knockout mouse models to test the role of Rap1 on
promoting RPE barrier properties, with emphasis on the dynamic junctional regulation that is triggered when the adhesion
between cells is challenged. In vitro, Rap1A shRNA reduced steady-state barrier integrity, whereas Rap1B shRNA affected
dynamic junctional responses. In a laser-induced choroidal neovascularization (CNV) model of macular degeneration,
Rap1b2/2 mice exhibited larger CNV volumes compared to wild-type or Rap1a2/2. In vivo, intravitreal injection of a cAMP
analog (8CPT-29-O-Me-cAMP) that is a known Rap1 activator significantly reduced laser-induced CNV volume, which
correlated with the inhibition of CEC transmigration across 8CPT-29O-Me-cAMP-treated RPE monolayers in vitro. Rap1
activation by 8CPT-29-O-Me-cAMP treatment increased recruitment of junctional proteins and F-actin to cell-cell contacts,
increasing both the linearity of junctions in vitro and in cells surrounding laser-induced lesions in vivo. We conclude that in
vitro, Rap1A may be important for steady state barrier integrity, while Rap1B is involved more in dynamic junctional
responses such as resistance to junctional disassembly induced by EGTA and reassembly of cell junctions following
disruption. Furthermore, activation of Rap1 in vivo inhibited development of choroidal neovascular lesions in a laser-injury
model. Our data suggest that targeting Rap1 isoforms in vivo with 8CPT-29-O-Me-cAMP may be a viable pharmacological
means to strengthen the RPE barrier against the pathological choroidal endothelial cell invasion that occurs in macular
degeneration.
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Introduction
The barriers created by epithelial and endothelial cell sheets in
the body are critical to maintain physiological homeostasis by
functioning to limit movement of fluids, solutes, macromolecules,
and the passage of other cells or pathogens from one side of a
monolayer to the other. The blood-brain and blood-retinal
barriers are extreme examples of this tight regulation. If the
integrity of the endothelial or epithelial barrier is compromised,
hyper-permeability, edema, inappropriate inflammation, and
invasion of non-resident cells can occur; this can lead to
pathologies in stroke and cardiovascular disease, autoimmune
disorders, tumor metastasis, and ocular diseases, including diabetic
retinopathy, retinal vein occlusion and age-related macular
degeneration (AMD).
Tight junctions and adherens junctions are sites of adhesion
between adjacent cells, and the transmembrane protein compo-
nents of these structures comprise the physical barrier of the
paracellular pathway. Transmembrane proteins, such as occludin,
members of the claudin family, and cadherins, also act as protein
scaffolds for cytoplasmic proteins such as ZO-1, b-, a-, and p120-
catenin, some of which bind to the actin cytoskeleton [1]. This
linkage between junctional complexes and the F-actin cytoskeleton
is critical for the dynamic opening and resealing of junctions, and
is necessary to allow rapid responses to cellular events. Further-
more, junctional adhesion may be strengthened to resist insult,
and/or repaired in response to challenge or injury. Of the
signaling proteins involved in junctional regulation, small GTPases
are particularly well-suited to rapid fine-tuning of barrier integrity
owing to their ability to cycle between active (GTP-bound) and
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inactive (GDP-bound) states. Small GTPases of the Rho family are
regulators of cell junctions [2,3]; how this occurs relates to the
ability of Rho GTPase signaling to affect actin cytoskeleton
remodeling [4].
In addition to the GTPases of the Rho family, we have also
become interested in another GTPase, Rap1, which is a member
of the Ras superfamily [5]. In addition to its role in integrin-
mediated cell matrix adhesion and cell migration [6], Rap1 has
been shown by many groups to regulate cell junctional integrity,
and barrier function of endothelial and epithelial cell monolayers
[7–13]; Rap1-induced junctional strengthening has been shown to
inhibit monocyte transendothelial migration [9]. There are two
isoforms of Rap1, Rap1A and Rap1B. Whereas Rap1a and Rap1b
knockout mice are each viable and fertile [14,15], the double
Rap1a/Rap1b knockout is lethal [16]. While Rap1a-null mice
were originally found to develop normally with no gross
phenotypic abnormalities [15,17], subsequent backcross into
C57Bl/6J background produced some (,40%) embryonic lethal-
ity associated with cardiac defects (J. Yan and L. Quilliam,
unpublished data). Rap1b-null mice exhibit 85% perinatal
lethality, likely due to complications arising from embryonic
hemorrhage [14]. Rap1A and Rap1B isoforms are on different
chromosomes, but are 94% identical, with only 9 amino acids
different between them, and oftentimes the literature has not
explicitly distinguished between the two. Recently, using in vitro
shRNA experiments in human endothelial cells, Rap1A was
shown to be the isoform important for attaining mature, steady
state junctional barrier properties [13].
The retinal pigment epithelium (RPE) makes up the outer blood
retinal barrier between the retina and the overlying sensory retina.
Breakdown of this barrier is a step in the pathogenesis of
neovascular AMD [18], the leading cause of central vision loss
world-wide in patients over the age of 60 years [19]. In
neovascular AMD, choroidal endothelial cells (CECs) are activat-
ed to migrate to, and across the RPE monolayer, leading to the
development of vision-impairing choroidal neovascularization
(CNV) in the sensory retina. As such, therapies in the form of
angiogenic inhibitors, including those acting against the bioactivity
of vascular endothelial growth factor (VEGF), have been the
mainstay of AMD treatment [20]; however, because VEGF is also
a neuroprotective agent [21] and a survival factor for endothelial
cells [22], inhibiting its bioactivity may not only inhibit CNV, but
also reduce these beneficial properties of VEGF. Therefore,
methods other than inhibition of angiogenesis to treat neovascular
AMD are under investigation, such as factors that regulate RPE




Animal care and use. All animals were cared for in
accordance with the Association for Research in Vision and
Ophthalmology Statement for the Use of Animals in Ophthalmic
and Vision Research; all animal use protocols were approved by
the Institutional Animal Care and Use Committee of the
University of Utah (IACUC protocol #10–06002), and of the
University of North Carolina (IACUC protocol #10–169).
Human samples. Primary human choroidal ECs (CECs)
were isolated from donor eyes (existing pathological specimens)
obtained from the North Carolina Eye Bank (http://www.
nceyebank.org) or the Utah Lions Eye Bank (http://www.
utaheyebank.org) as described previously [23].
Cell Culture
ARPE-19 cells (RPE) were obtained from ATCC (Rockville,
MD), grown in DMEM/F-12 plus 10% FBS, and used from
passage 15–20 when epithelioid properties are still present [24].
CECs were grown in endothelial growth media (EGM-2; Lonza,
Walkersville, MD) supplemented with 10% FBS and used from
passage 2–4.
shRNA of Rap1A and Rap1B
Adenoviral constructs encoding microRNAs designed to specif-
ically target and knockdown expression of Rap1A or Rap1B have
been described previously [13]. Negative control shRNA adeno-
virus expresses an insert that is processed into a mature shRNA,
but it is not predicted to target any known vertebrate gene. In
ARPE-19 cells, efficient knockdown was attained 48 to 72 hours
post-virus addition. Confirmation of knockdown was obtained by
Western blot analysis of cell lysates using primary antibodies that
specifically recognize Rap1A or Rap1B isoforms (anti-Rap1A
rabbit pAb SC-1482R, Santa Cruz; anti-Rap1B rabbit mAb
#2326S, Cell Signaling Technology), or an antibody that
recognizes both isoforms (A+B) (Santa Cruz #sc-65),. Equal gel
loading was confirmed by probing with anti-b-actin (MAB1501,
Chemicon).
Calcium Switch Assays
The ‘‘calcium switch’’ assay is a method for assessing cell
junctional disassembly and reassembly, using EGTA treatment
and subsequent washout as a means of inducing dynamic changes
in barrier function that can be measured experimentally [25]. For
calcium switch experiments, ARPE-19 cells were cultured on
coverslips, and then transduced with negative control, Rap1A, or
Rap1B shRNA construct for another 3 days before performing the
calcium switch assay. EGTA (4 mM) was added for 5–30 minutes
to disrupt junctions; washout with calcium-containing cell growth
media for 0.5–24 hr stimulated synchronous junctional resealing.
Analysis of Monolayer Gaps
At the indicated time points of EGTA addition or washout,
ARPE-19 cell monolayers were fixed and stained as described
previously [26]. Fluorescence images were obtained with an
Axiovert 200 M microscope (Zeiss,) equipped with a digital
camera (Hamamatsu ORCA-ERAG) and acquired using Meta-
morph (Universal Imaging Corp.). To quantify RPE monolayer
integrity, images taken from multiple random fields were analyzed
in ImageJ by thresholding and using the ‘‘area fraction measure-
ment’’ tool to obtain the number of pixels representing the area
not covered by cells, and expressed as percent gap area of the total
area of the image field. Prior to image analysis, file names were
randomized to ensure unbiased analysis. Cell area was readily
identified by cytoplasmic fluorescence from the cocistronically
expressed EmGFP contained within the shRNA expression
cassette.
Barrier Function Assays
Transepithelial Electrical Resistance (TER). ARPE-19
were plated at confluent density (1.86105 cells) on 12 mm
diameter, 0.4 mm pore size Transwell filters (in at least quadru-
plicate). TER was measured at given time points using an
Endohm-12 Transwell Chamber connected to an EVOM
Voltohmmeter according to the manufacturer’s instructions.
‘‘Day 0’’ TER readings were taken immediately before shRNA
virus addition; steady state TER was measured again at day 5
post-infection. Data for these experiments are expressed as
Rap1 GTPase and RPE Barrier Function In Vivo
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normalized TER relative to the initial day 0 value (average from
n=3 independent experiments).
Real-time cell analysis (RTCA) experiments. Barrier
properties of RPE were also measured using the xCELLigence
Real-Time Cell Analyzer (RTCA) system (Acea Biosciences/
Roche Applied Science). This technology measures electrical
impedance as a readout for the barrier status of cells grown
directly on biocompatible micro-electrode coated surfaces. Chang-
es in impedance (represented as ‘‘Normalized Cell Impedance’’)
reflect changes in barrier function and permeability [27,28].
ARPE-19 treated with indicated shRNA were grown on the
microelectrode-coated wells of an E-Plate 16 (Roche Applied
Science), and then treated with 4 mM EGTA to induce barrier
breakdown. Monolayer impedance was recorded at 1 min
intervals for 90 min in the presence of EGTA. A representative
trace from 3 independent experiments is shown, graphed as
average of quadruplicate wells 6 SD.
CEC Transmigration Assay
CEC transmigration across the RPE monolayer was measured
as previously described with minor modification [23]. Briefly,
ARPE-19 cells were plated onto the underside of 8 mm pore size
Transwells (Costar/Corning), and were treated with 250 mM
8CPT-29O-Me-cAMP (Biolog) overnight. Primary human CECs
were fluorescently-labeled (VybrantDio Cell-labeling solution;
Invitrogen), and then plated in the top well of the inserts. After
48 h, CECs which had migrated across the filter and the RPE,
were counted per 206 field by fluorescence microscopy. Multiple
random fields were quantified, averaged, and data presented as
mean 6 SEM from 6 Transwells per condition.
In vivo Laser-induced CNV Model
Wild type (WT) C57/Bl6 mice were litter-mate controls from
Rap1a or Rap1b knockout mice. Rap1a2/2 and Rap1b2/2 mice
were as described [14,29]. Mice aged between 11–20 weeks were
used for these studies.
Laser treatment. The laser-induced choroidal neovascular-
ization (CNV) model was carried out as previously described [30].
Briefly, 11–20 week old mice were anesthetized then raised on a
platform to the slit lamp (30 SL-M, Carl Zeiss Meditec Inc. CA) to
perform laser photocoagulation (150 mW, 100 ms, 100 mm) using
a 532-nm OcuLight GL laser (Iridex, Irvine, CA).
RPE/Choroid Flat mount. Eyes were enucleated then fixed
in 4% paraformaldehyde/PBS for 1 hr, then posterior eyecups
consisting of the RPE/choroid/sclera were dissected out. Eyecups
were treated with 0.1% Triton X-100 before labeling for indicated
junctional proteins. Primary antibodies: anti-b-catenin (pAb
C2206, Sigma), anti-ZO-1 (mAb clone1A12, Invitrogen); F-actin
was visualized using Texas Red-conjugated phalloidin and nuclei
by Hoechst 33342 (Invitrogen). For visualization of laser lesions,
eyecups were stained with AlexaFluor 568-conjugated isolectin B4
(Invitrogen, CA) overnight at 4uC to label invading choroidal
vessels. After staining, the eyecups were flattened by cutting radial
incisions and flat-mounted onto a microscope slide with Vecta-
shield mounting medium (Vector Laboratories).
Quantification of b-catenin junctional
localization. Images were analyzed for b-catenin fluorescence
intensity at cell-cell contacts using ImageJ (National Institutes of
Health) as described in [31]. Briefly, mean pixel intensity of
immunolabeled b-catenin was measured in a small (25 mm2)
circular region of interest (ROI) drawn over a cell junction (two
opposing cell membranes). For each measurement, cytoplasmic
background was subtracted by moving the circular ROI to a
region immediately adjacent to the measured junction. A total of
100 cell-cell junctions were measured per condition.
Confocal Imaging and Quantification of Lesion
Volume. Flat mounts were imaged by taking optical Z-sections
at 1 mm increments with a confocal microscope (Olympus
FV1000) and summing areas to create a volume. Confocal stacks
were analyzed with 3D image-analysis software (Volocity 5.0;
Improvision/PerkinElmer) to obtain each isolectin-positive lesion
volume (mm3). Lesions with obvious hemorrhage or bridging CNV
were excluded. For experiments comparing WT and knockout
mice, 17–26 lesions, from at least 6 mice per genotype were
analyzed. For 8CPT-cAMP dose experiment, 13–21 lesions from
at least 4 mice injected with each dose were analyzed.
In Vivo Rap1 activation with 8CPT-cAMP
Intravitreal injection was done using a MICROLITERTM
syringe (Hamilton Company) immediately after laser administra-
tion. 8CPT-cAMP was injected at doses that have been shown to
activate Rap1, but not PKA (i.e. ,100 mM, [32]), each in a
volume of 1 ml. Phosphate buffer saline (PBS) injection was used as
the control.
Rap1 Activity Assays. Three to four hours following laser
injury and intravitreal injection of 8CPT-cAMP (2.05 mM) or
PBS, RPE/choroids were isolated from euthanized mice, and
lysed and homogenized by sonication in RIPA buffer. Superna-
tants were used for Western blotting using an antibody specific for
active (GTP-bound) Rap1 (NewEast, PA), and b-actin (Santa
Cruz, CA). Digitized images of Western blots were quantified
using UN-SCAN-IT gel 6.1 (Silk Scientific) and normalized to b-
actin.
Quantification of Junctional Linearity. A ‘‘junctional
linearity index’’, defined as the ratio of actual junction length to
the linear junction length (straight line distance between vertices)
was calculated as described [33]. Cell junctions were manually
traced and measured using ImageJ. The closer the value to ‘‘1’’,
the higher the degree of linearity.
In Vivo Toxicity Assays
Retinal Thickness. Following laser and vitreous injection of
8CPT and PBS, retinal thickness measurements were taken with a
spectral-domain optical coherence tomography unit (sd-OCT;
Bioptogen, NC), in 2–4 discrete locations in each eye. Locations
were 2 optic nerve disc diameters from the optic nerve and
avoided areas encompassing laser lesions. Retinal thicknesses of 18
eyes for each condition were obtained to compare 8CPT vs. PBS
injection, and image analysis was done with InVivoVue Clinic
software.
Cleaved-caspase3 assay. 24 hr following administration of
8CPT-cAMP or PBS, mice were euthanized and the RPE/
choroids were isolated, lysed in RIPA buffer, and homogenized
using sonication. Supernatants were collected and blotted for
cleaved caspase-3 (Cell Signaling, MA) and for total caspase-3. As
a positive control for apoptosis, H1B-1B cells were treated with
staurosporine (1 mM, 3 hr at 37uC), and then blotted for cleaved
caspase-3.
TUNEL Staining. Eyes were fixed in 4% PFA, incubated in
15% sucrose until sinking, and then incubated in 30% sucrose
overnight at 4uC. Samples were then embedded in O.C.T.
Compound, frozen rapidly with dry ice, and stored at 280uC until
sectioning. Cryosections with thicknesses of 10 to 12 mm were
prepared using a cryostat (CM3050S, Leica, NJ). Apoptotic cells
were visualized by TUNEL using the In Situ Cell Death Kit-
Fluorescein (Roche Diagnostics, Germany) according to manu-
facturer’s protocol. DNase-treated cryosections (Fermentas-
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EN0521; 0.33 U/ml in PBS, 30 min) served as a positive control
for TUNEL assay.
Statistical Analysis
In vitro experiments. Statistical significance was determined
by Student’s t-test (one-tail, equal variance) using the average
values 6 SEM obtained from at least triplicate samples in a given
experiment, or normalized pooled data from at least 3 indepen-
dent experiments, unless noted in the figure legend. A P value of
,0.05 was considered statistically significant. Immunofluorescence
data, including confocal imaging and Western blot analyses are
representative of multiple independent experiments.
In vivo experiments. Mean CNV volume of lesions for
Rap1a2/2 and Rap1b2/2 mice, each dose of 8CPT-cAMP, and
control were analyzed by Kruskal-Wallis test. Active Rap1 in
RPE/choroids was analyzed by ANOVA. Post-hoc testing was
performed using the Fisher’s LSD test for parametric tests and the
Steel-Dwass test for non- parametric tests. An alpha level of ,0.01
was used as criterion of significance.
Results
While previous work has implicated Rap1 in cell junction
regulation, information is still lacking on isoform-specific functions
for Rap1A and Rap1B, both during maintenance of mature
junctions at steady state and during the dynamic junctional
regulation that must occur during assembly and disassembly. We
treated RPE cells in vitro with Rap1 isoform-specific shRNA
constructs [13,26], and assessed monolayer integrity and barrier
function under both of these conditions. Confirmation of
knockdown and antibody specificity is shown in Fig. S1. shRNA-
treated RPE were plated for 4–5 days to allow stable cell
monolayers to develop. Representative immunofluorescent images
of ZO-1 localization at steady state (Fig. 1A) show that control and
Rap1B shRNA monolayers exhibit a continuous junctional ZO-1
staining pattern with very few gaps between cells. By contrast,
Rap1A shRNA RPE seemed to have more discontinuous ZO-1
staining and greater gaps between cells in the monolayer
(arrowheads). Monolayer integrity was quantified using image
analysis software to measure the average gap area of each shRNA
monolayer from multiple random fields (Fig. 1A, graph). Rap1A
shRNA-RPE monolayers had significantly greater gap area than
either control or Rap1B shRNA monolayers, indicating that at
steady state, Rap1A is important for maintenance of a confluent,
gap-free monolayer. We also examined these shRNA-treated RPE
using transepithelial electrical resistance (TER) as a read-out of
monolayer barrier function. TER was measured before indicated
shRNA-treatments (‘‘day 0’’) and again after 5 days (Fig. 1B). Both
negative control and Rap1B shRNA-treated RPE monolayers had
significantly higher TER at day 5 compared to day 0; however,
the TER of Rap1A shRNA-treated RPE did not increase
significantly over the same time period. Steady state TER after
5 days was significantly lower in Rap1A shRNA monolayers
compared to control and Rap1B shRNA. The observations that
Rap1A shRNA increased monolayer gap area and decreased TER
imply that Rap1A may be more important for acquisition of steady
state TER.
To examine RPE cell junctions under dynamic disassembly/
reassembly conditions, we also subjected shRNA-treated RPE
monolayers to a calcium switch protocol as described in the
Materials and Methods. Representative immunofluorescent imag-
es of ZO-1 localization in negative control vs. Rap1A or Rap1B
shRNA cells subjected to calcium switch are shown in Fig. 2A and
Fig. S2. While all cell monolayers exhibited loss of junctional ZO-
1 staining along with cell retraction and appearance of monolayer
gaps after 30 min EGTA treatment, quantification of the gap area
(graph at right) revealed that Rap1B shRNA caused significantly
greater monolayer disruption (greater gap area). After 1–3 hr
EGTA washout, junctions of the control and Rap1A shRNA
monolayer were beginning to reseal, with the recruitment of ZO-1
becoming apparent and the monolayer gap size decreasing. In
contrast, Rap1B shRNA cell monolayers show delayed reassembly
of cell junctions, as evidenced by incomplete junctional relocaliza-
tion of ZO-1 after a 3 hr washout and the persistence of
monolayer gaps even after 24 hr washout. We also looked at
junctional disassembly by treating cell monolayers to an EGTA
time course and quantifying monolayer gap area (Fig. 2B). At each
time point, Rap1B-shRNA RPE monolayers had significantly
greater gap area than control or Rap1A shRNA-treated mono-
layers. Finally, we confirmed that this increase gap area
corresponded with barrier function by performing real time
cellular analysis of electrical impedance (RTCA) of cell monolay-
ers. shRNA-treated monolayers were grown as a monolayer on
micro-electrode coated surfaces, and then EGTA was added
(arrow) to induce junctional disassembly (indicated by a decrease
in Cell Impedance). Representative impedance trace (Fig. 2C)
shows that barrier function, measured by impedance, is decreased
more in Rap1B shRNA monolayers treated with EGTA compared
to control or Rap1A shRNA monolayers. There was no significant
difference between control or Rap1A shRNA treated monolayers.
Taken together, these results imply that in vitro, loss of Rap1A
impairs steady state junctional maintenance under control
conditions (Fig. 1A–B), whereas loss of Rap1B affects more
dynamic events such as junctional reassembly/disassembly
(Fig. 2A–C).
Breakdown of the RPE barrier during neovascular AMD is an in
vivo example of a situation where impaired junctional resealing
would contribute to the pathology. Our in vitro results led us to
explore whether Rap1A and/or Rap1B are key to the mainte-
nance of this barrier. We turned to a well-accepted in vivo model of
choroidal neovascularization induced by laser injury (laser-CNV)
[30] to explore whether loss of Rap1 inhibits RPE barrier function
and facilitates CNV formation. In this model, the laser dramat-
ically disrupts the RPE monolayer locally where the laser spot is
administered. While some RPE cells directly in the laser spot are
destroyed, neighboring RPE produce reactive oxygen species that
can be measured by dihydroethidium staining [34]. This and other
inflammatory and wound-healing events occur that lead to
activation of CECs from the choriocapillaris to migrate and
proliferate within subretinal space to form CNV lesions. One week
post-laser, we analyzed extent of CNV as width of lesion at the
RPE layer measured by spectral domain-optical coherence
tomography (sd-OCT) and volume by measuring and summing
areas axially obtained at 1 mm intervals by confocal microscopy of
lectin-stained RPE/choroid flat mounts from WT, Rap1a2/2, and
Rap1b2/2 mice. Representative maximum projections of lectin-
stained CNV are shown in Fig. 3A. Quantification of lesion
volume revealed that Rap1b2/2 had significantly larger CNV
volumes compared to either WT or Rap1a2/2 (Fig. 3B).
Based on these results, we hypothesized that conversely, CEC
transmigration and CNV formation would be reduced by
activating Rap1 isoforms in RPE. 8CPT-29-O-Me-cAMP
(8CPT-cAMP) is a cAMP analog that binds to and activates the
Rap1 exchange factors Epac1 and Epac2, but does not activate
other cAMP-responsive pathways involving PKA and other
downstream pathways [32]. In cultured RPE cells, treatment with
250 mM 8CPT-cAMP is sufficient to activate total Rap1 and
increase monolayer barrier function (cellular impedance) [26].
Rap1 GTPase and RPE Barrier Function In Vivo
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Furthermore, Rap1 activation by 8CPT-cAMP treatment of RPE
caused stress fiber dissolution, stabilizing the cortical localization of
F-actin (Fig. 4A), similar to published reports for other cell types
[10,35–38]. ZO-1 was also enriched at cell junctions with the
localization appearing more linear and continuous, having fewer
cells with punctate discontinuous ZO-1 staining compared to PBS-
treated (Fig. 4B, insets upper right). In short-term culture
experiments like this, ARPE can exhibit some discontinuous
staining at baseline, which we use to represent RPE in ‘‘stressed or
aged’’ conditions. When quantified, 8CPT-cAMP treatment was
confirmed to significantly enhance the junctional recruitment and
linear pattern of ZO-1 compared to PBS-treated control (Fig. 4C).
We then asked whether this also occurred in vivo upon 8CPT-
cAMP intravitreal injection. Fig. 4D shows representative confocal
images of flat mounted murine eyes that had been injected with
PBS or 8CPT-cAMP. 8CPT-cAMP injection induced a slight
increase in F-actin localization to the cell periphery, and
reorganized cell junctions to a more linear shape. b-catenin
junctional localization was also reorganized after 8CPT-cAMP
intravitreal injection. Quantification of b-catenin pixel intensity
confirmed a significant increase in junctional localization after
8CPT-cAMP treatment (Fig. 4E).
We then tested whether the barrier enhancing-effects of
activating Rap1 with 8CPT-cAMP could protect against CEC
transmigration across RPE grown as inverted monolayers on
Transwell filters [23,39]. Compared to the PBS-treated control,
8CPT-cAMP treatment significantly reduced CEC transmigration
across the RPE monolayer in vitro (Fig. 5A). Next, we tested
whether activation of Rap1 in vivo would abrogate laser-induced
CNV. 8CPT-cAMP at indicated doses was administered by
intravitreal injection [40] immediately following laser, and CNV
volumes were quantified 1 week later. Representative confocal
images of lectin-stained flat mounts of PBS and 20.5 mM 8CPT-
cAMP-injected eyes are shown in Fig. 5B. Compared to PBS-
injected control, there was a dose-dependent decrease in CNV
volume with increasing concentration of drug (Fig. 5C). We
Figure 1. Rap1A knockdown in vitro impairs steady state monolayer integrity and decreases transepithelial electrical resistance. (A)
RPE cells transduced with indicated shRNA constructs were grown on coverslips for 4–5 days to obtain steady state monolayers. Top row,
representative immunofluorescence localization of the junctional marker ZO-1. Scale bar = 50 mm. Boxed areas are enlarged to highlight intercellular
gaps in Rap1A shRNA cell monolayers (bottom row). Scale bar = 25 mm. Quantification of total monolayer gap area per image field (expressed as % of
total field area) using image analysis software (ImageJ) was used as an indication of monolayer integrity. Graph shows the mean of n = 4 fields6 SEM,
representative experiment from 2 independent trials. **p,0.01, 1A shRNA compared to both Neg and 1B shRNA. (B) TER was measured on cells prior
to shRNA knockdown (day 0), and again after 5 days. Graph shows TER of negative control, Rap1A, or Rap1B shRNA treated cells, representing
average TER normalized to control at t = day 0 from n=4 independent experiments. Control shRNA and Rap1B shRNA cells increased TER after 5 days
in culture, while Rap1A shRNA cells did not significantly increase TER from day 0 to day 5. * p#0.01, NS = not significant; **p#0.01, TER of Rap1A
shRNA monolayers significantly lower at steady state (day 5) compared to control and Rap1B shRNA.
doi:10.1371/journal.pone.0073070.g001
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Figure 2. Rap1B knockdown in vitro affects dynamic junctional responses. Monolayer re-formation and resistance to EGTA-induced
junctional disassembly were assessed using the calcium switch assay. (A) Representative immunofluorescence localization of ZO-1 after 30 min EGTA
to disrupt junctions (left column), followed by 1 or 3 hr of washout to synchronously initiate junctional re-assembly (middle and right columns). Note
greater cell-free areas (gaps) and impaired recruitment of ZO-1 to cell-cell contacts in Rap1B shRNA RPE. Quantification of the monolayer gap area per
image field is shown in the graph. Recovery of Rap1B shRNA monolayer integrity was delayed compared to Neg control and Rap1A shRNA. (*
compared to Neg, ** compared to Neg and Rap1A shRNA). Pooled averages (multiple random fields) from n= 3 independent experiments 6 SEM,
normalized to gap area of Neg control monolayers after EGTA treatment. *, **p#0.05 (B) Gap area during EGTA-induced junctional disassembly was
quantified as in panel A. EGTA treatment caused larger gaps in Rap1B shRNA monolayers compared with control or Rap1A shRNA monolayers. Graph
shows the mean of n= 4 fields 6 SEM, representative experiment from 2 independent trials. *p#0.05, 1B shRNA compared to both Neg and 1A
shRNA. (C) Electrical impedance analysis of cell monolayer disruption induced by EGTA. Data points represent the average 6 SD from quadruplicate
wells for each condition. Representative trace of 3 independent experiments.
doi:10.1371/journal.pone.0073070.g002
Figure 3. Laser-induced CNV in WT vs. Rap1a2/2 and Rap1b2/2 mice. One week following laser, eyes were processed as RPE/choroid flat
mounts and stained with AlexaFluor 568-labeled lectin to visualize the choroidal neovascular endothelial cells. (A) Representative confocal images
from WT, Rap1a2/2, and Rap1b2/2 (maximum projections). (B) Quantification shows that CNV volume is significantly greater in Rap1b2/2 compared
to WT and Rap1a2/2 mice. Bars represent average lesion volume 6 SEM from at least 6 individual mice per genotype (n = 17–26 lesions). * p,0.01,
Rap1b2/2 compared to WT and Rap1a2/2.
doi:10.1371/journal.pone.0073070.g003
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confirmed that treatment with 8CPT-cAMP increased Rap1
activity in isolated RPE/choroids following intravitreal injection
(Fig. 5D). Furthermore, we tested for toxicity of intravitreal
injection of 8CPT-cAMP. There was no significant difference in
retinal thickness measured by sd-OCT in PBS vs. 8CPT-cAMP-
injected eyes (Fig. S3A–C). In addition, cleaved caspase-3, a
cellular marker indicator of increased apoptosis, was not detected
in PBS or 8CPT-cAMP-injected eyes 24 hours after injection
(Fig. S3D). Lastly, there was negligible amount of positive TUNEL
staining of cryosections of injected eyes (Fig. S3E). These
measurements all indicate that toxicity of 8CPT-cAMP was low.
Combined, these results indicate that activation of both Rap1
isoforms in RPE with 8CPT-cAMP treatment can inhibit
transmigration of CECs across the epithelium in vitro, and this
correlated with decreased CNV volume in vivo.
One mechanism that has been proposed to explain the pro-
junctional effects of active Rap1 is enhanced recruitment of
junctional proteins and cortical F-actin to sites of cell-cell contact
[8,41]. We examined recruitment of F-actin and b-catenin to RPE
cells bordering laser-induced lesions in eyes injected with PBS vs.
8CPT-cAMP. Confocal imaging of these lesions showed an
enrichment of junctional F-actin staining in 8CPT-cAMP-injected
eyes, particularly in the RPE cells immediately adjacent to the
lesion (Fig. 6A–B). Enhanced b-catenin staining and a more linear
Figure 4. Activation of total Rap1 enhances recruitment of junctional proteins and cortical F-actin both in vitro and in vivo. (A) 8CPT-
cAMP treatment (250 mM, 1 hr) of cultured RPE monolayers decreases stress fibers and enhances cortical F-actin morphology. (B) Enhanced
recruitment and linear junctional staining of ZO-1 with 8CPT-cAMP treatment compared to PBS control. Boxed areas are enlarged in the upper right
inset to highlight differences in junctional staining pattern. Scale bar, 50 mm (C) Quantification of in vitro 8CPT-cAMP treatment. Percent of cells that
show enhanced (linear) junctional localization of ZO-1 (average % of 10 fields/condition (.600 cells total counted). * p,0.01 (D) In vivo, eyes injected
with 8CPT-cAMP also have enhanced linear junctional recruitment of proteins such as F-actin and b-catenin. (E) Quantification of junctional b-catenin
in PBS vs. 8CPT-cAMP-injected eyes. Data plotted as average junctional pixel intensity from random cells per field, from n= 4 injected eyes (.100
cells). * p = 0.0324 compared to PBS-injected.
doi:10.1371/journal.pone.0073070.g004
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localization around the cell periphery were also observed in
8CPT-cAMP injected eyes. Changes in cell shape and junctional
linearity has been correlated with increased junctional integrity
and function [33,42]. A ‘‘junctional linearity index’’ was calculated
as described in Materials and Methods, and representative
example cell values are shown in Fig. 6C for visual reference.
RPE cells surrounding the lesions in 8CPT-cAMP injected eyes
had significantly greater linearity (i.e. values approaching ‘‘1’’)
(Fig. 6D). These observations suggest that increased recruitment of
junctional proteins, F-actin, and enhanced junctional linearity may
be a mechanism for the increased barrier properties of the RPE
when Rap1 is activated with 8CPT-cAMP.
Discussion
Our previous study implicated the small GTPase, Rap1, in
promoting barrier integrity of an RPE cell monolayer in vitro [26];
however, it did not dissect the relative role of each isoform.
Furthermore, whether active Rap1 contributed to enhanced
barrier function of the RPE in vivo, and importantly, whether
activation of Rap1A or 1B was relevant to mechanisms relating to
choroidal neovascularization, remained to be determined. Using a
coculture model relevant to several pathways involved in human
AMD [18,39,43,44] and an in vivo mouse model of laser-induced
CNV, we show that loss of Rap1B in vivo results in increased CNV.
One possible mechanism for this would be impaired ability of RPE
cell-cell junctions to dynamically respond to challenge (i.e. laser-
injury) in the absence of Rap1B. Significantly, we can inhibit CNV
following laser injury by intravitreal injection of 8CPT-29-O-Me-
cAMP, a compound that activates both Rap1 isoforms. We
attribute this effect to the Rap1-induced enhancement of RPE
barrier function, via reorganization of cortical F-actin, and
possibly the increased recruitment of junctional proteins in cells
at the lesion margins.
In endothelial cells (HUVECs), loss of Rap1A significantly
reduced impedance and monolayer integrity, and loss of Rap1B
had no effect on steady state cell junctional properties [13]. In
RPE cells, we show that at steady state, knockdown of Rap1A, but
not Rap1B, increased monolayer gap area and decreased TER in
vitro (Fig. 1), in keeping with these previous observations. In the
current study, we also looked at the effects of Rap1 isoform
knockdown during dynamic processes such as disassembly/
reassembly. Surprisingly, our results revealed that Rap1B shRNA
RPE cell monolayers had delayed recovery following washout
(Fig. 2A), and were less resistant to EGTA-induced disassembly
(Fig. 2B–C), compared to control shRNA or Rap1A shRNA
monolayers. We have observed similar Rap1 isoform-specific
effects on both steady state and dynamic junctional regulation
using primary lung endothelial cells isolated from Rap1a and
Rap1b mutant mice (M. Sobczak and M. Chrzanowska-Wod-
nicka, unpublished data). The distinction between steady state and
dynamic junctional regulation is important, as cellular barriers
must have intrinsic baseline barrier properties to maintain
homeostasis, but must also be primed to respond to various
stressors.
We therefore turned to a model in which we could introduce a
challenge to the integrity of the RPE barrier. In the laser-CNV
model, focal laser-induced thermal and mechanical damage to
RPE and Bruch’s membrane allows the underlying activated
CECs to proliferate, migrate, and invade the retina to form CNV.
In the model, CECs can migrate through the lasered region that is
void of RPE. In addition, laser induces reactive oxygen species
[34], angiogenic [44,45] and inflammatory factors [46] that
compromise barrier integrity of the surviving neighboring RPE,
which then cannot resist CEC transmigration into the sensory
retina. These events can further increase CNV lesion size. The
murine laser-induced CNV model is relevant to human neovas-
cular AMD based on sharing of key molecular mechanisms, and
Figure 5. CEC transmigration across RPE monolayer (in vitro) and CNV volume (in vivo) are inhibited with 8CPT-cAMP treatment. (A)
In vitro, CECs have decreased transmigration across RPE monolayers when RPE are incubated with 8CPT-CAMP. Representative experiment of 2
independent trials. Data plotted as the average number of transmigrated CECs (6 SEM) per 3 random fields, n = 6 Transwells per condition. * p,0.001
(B) Representative confocal images (maximum projections) of lectin-stained RPE/choroid flat mounts, 1 week post laser and intravitreal injection of
PBS or 20.5 mM 8CPT-cAMP. (C) Quantification: intravitreal injection of 8CPT-cAMP induces a dose-dependent decrease in CNV volume in compared
to PBS-injected control. *p,0.01, **p,0.001 (n = 13–21 lesions per condition) (D) Intravitreal injection of 8CPT-cAMP activates Rap1 in vivo. RPE/
choroid was dissected and lysates were blotted with an antibody that detects active Rap1 (GTP-bound), or b-actin as loading control. Graph shows
densitometry of active Rap1 normalized to b-actin (average 6 SEM, n = 6). * p,0.0001.
doi:10.1371/journal.pone.0073070.g005
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the observation that laser injury can also cause CNV in humans
[47]. In AMD, CNV of the normally avascular photoreceptor
region of the macula is a major cause of vision loss.
When we induced injury to the RPE by laser photocoagulation
and subsequently monitored the neovascular response, we found
differences between WT and Rap1a or Rap1b knockout. Following
laser, mice lacking Rap1B had significantly greater CNV volume
compared with WT and Rap1a2/2 mice (Fig. 3A-B). This result
coincides with our in vitro studies showing that Rap1B shRNA RPE
monolayers weremore sensitive to EGTA-induced disassembly, and
Figure 6. Recruitment of junctional proteins and increased junctional linearity adjacent to lesions. (A) b-catenin and F-actin staining
around lesions is enhanced in 8CPT-injected eyes. Scale bar, 100 mm (B) Magnified view of boxed areas of panel A. Lesion margin is demarcated by
dotted line. Scale bar, 50 mm (C) ‘‘Linearity Index’’ was quantified for randomly selected cells surrounding a lesion as the ratio of actual junctional
length (green) to the linear junction length (straight line between vertices; red). Two sample traced cells and the corresponding linearity index are
shown. (D) Linearity index of cells adjacent to lesion is significantly closer to ‘‘1’’ in 8CPT-cAMP-injected eyes. Graph represent average cell linearity
index 6 SEM, from n= 7 lesions per condition. * p = 1.576361027.
doi:10.1371/journal.pone.0073070.g006
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were slower to re-assemble cell junctions (Fig. 2). Thus, we
hypothesized that in Rap1b2/2 eyes the RPE, particularly those
adjacent to the lasered regions, are less able to recover from the laser
injury and activated CECs can more easily breach the RPE
monolayer barrier (Fig. 7 schematic). In the laser-CNV model,
day 7 marks the early stages of CNV-complex regression, initiated
by proliferation andmigration of theRPEover the fibrovascular scar
[48]. Containment of migrated CECs in the neovascular tissue [49]
would also be aided by re-sealing of RPE cell-cell junctions. CNV
volume is a product of both RPE barrier disruption and CEC
migration/proliferation into the neurosensory retina. In addition,
CECs also have cell-cell junctions, breakdown of which would
likewise encourage migration and invasion into the sub-RPE or
sensory retinal spaces. Rap1A alone [50], or together with Rap1B
[29,51–53], has been shown to be required for efficient cell
migration, including angiogenesis, but the results have varied
depending on cell type. RPE- and CEC-specific knockout or
conditional activation of each Rap 1 isoform in RPE would be
required to test in which cell type each isoform plays its more critical
role. The involvement of each isoform may depend on cellular
context, stimulus, or model system used.
Based on our Rap1 knockout mouse experiments, we hypoth-
esized that conversely, targeted activation of Rap1 in the RPE
would provide a novel approach to inhibit CEC transmigration of
the RPE and ultimately, reduce CNV. To test the idea that
strengthening the RPE barrier could decrease CEC invasion, we
utilized 8CPT-cAMP, a chemically modified cAMP analog that
can increase the activity of both Rap1 isoforms via activation of
the Rap GEF Epac, but does not activate other cAMP-responsive
pathways [32]. In vitro, treatment of cultured RPE cells with
8CPT-cAMP significantly reduced transmigration of CECs across
the cell monolayer (Fig. 5A). We also found that intravitreal
injection of 8CPT-cAMP immediately following the laser-injury
significantly reduced CNV volumes (Fig. 5B–C). Intraocular
injections are the delivery method of choice for traditional AMD
therapies targeting VEGF, and are not an unreasonable method of
delivery. We have also carefully measured various indicators of
toxicity to rule out unwanted side effects (Fig. S3). Other groups
have shown that Rap1 activation in vivo by methods including
8CPT-cAMP treatment can reduce microvascular permeability
[35,54], protect against renal failure in ischemia-reperfusion injury
[55], and inhibit lung vascular leak in ventilator-induced lung
injury [12]; our findings suggest Rap1 activation may also be a
valid pharmacological strategy to strengthen RPE barrier prop-
erties and prevent choroidal neovascularization that occurs in
AMD. That being said, activating Rap1 in vivo could also
strengthen CEC junctions, which could enhance the protective
effect of 8CPT-cAMP treatment in inhibiting CNV. CNV can
occur either sub-retinal (Type 2), where the RPE layer is breached,
or sub-RPE (Type 1, ‘‘occult’’), where invading CECs remain
below the RPE. When visual acuity falls in neovascular AMD,
about 50% of the time it is from the transition from Type 1 occult
Figure 7. Schematic of cellular events in the laser CNV model. Laser treatment creates a breach in RPE and Bruch’s membrane; RPE barrier
integrity is compromised in cells adjacent to the lasered region. Inflammatory and wound healing events lead to activation of CECs from the
choriocapillaris; CECs begin to migrate and transmigrate the lasered lesion as well as the adjacent RPE with compromised barrier integrity. In Type 2
CNV (shown), CECs proliferate and invade the subretinal space to form CNV. Type 1 (occult) CNV occurs when CECs remain sub-RPE (not shown in this
model). 8CPT-cAMP injection post-laser inhibits CNV by promoting barrier integrity in the neighboring RPE, thereby reducing the lesion width
through which CECs migrate. CEC junctional integrity may also be strengthened, contributing to the decreased CNV. Compared to WT, Rap1b2/2 RPE
cell junctions are more easily disrupted, allowing greater CEC transmigration and increased CNV. 8CPT-cAMP treatment activates both Rap1 isoforms,
which is associated with increased junctional resealing and limits RPE monolayer disruption through which CEC migration occurs.
doi:10.1371/journal.pone.0073070.g007
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CNV to Type 2 sensory retinal CNV [56]. A junction-promoting
effect on CECs would also inhibit either type of CNV.
Once Rap1 is activated, it can then signal to other downstream
barrier-promoting signaling pathways in the cell. For example,
under certain conditions active Rap1 has been shown to interact
with a subset of Rac1 GEFs, such as Tiam1 and Vav2 [57],
recruiting these GEFs to the leading edge lamellipodium where
they promote localized Rac1 activation and enhanced cell
spreading. With respect to barrier function, the Rac1 GEFs
Vav2 and Tiam1 have been implicated in increased TER and
formation of cortical F-actin following prostaglandin or atrial
natriuretic peptide treatment [58,59]. In contrast, activation of
Rho GTPase is associated with dissolution of cortical F-actin
structures and production of cytoplasmic stress fibers, with the
result being increased myosin-based contractility and increased
permeability (reviewed in [60,61]). Rac1 activation may counter-
act RhoA activity via redox signaling [62]. Thus, the potential
cross-talk between Rap1 and other GTPases such as Rac1 and
RhoA is an interesting avenue for future research.
The mechanism for barrier function regulation most often
attributed to Rap1 activation is enhancement of junctional protein
localization, as well as changes in F-actin distribution. We
observed that 8CPT-cAMP treatment promoted an increase in
cortical F-actin (Fig. 4A). An increase in cortical actin would
provide a means of linking the actin cytoskeleton to cell-cell
junctions, and has been associated with the enhanced barrier
function of ‘‘mature’’ junctions [10,35–37]. Furthermore, we also
observed recruitment of junctional proteins such as ZO-1 and b-
catenin to a more continuous, linear pattern both in vitro and in vivo
(Fig. 4). This was particularly apparent in the RPE cells adjacent to
the laser lesion (Fig. 6), suggesting an active process of remodeling
in these regions. Rap1 is known to bind to multiple junctional
proteins, and positive and negative regulators of Rap1 are also
recruited to cell junctions (reviewed in [63]). Rap1 undergoes
rapid activation during calcium switch experiments when cell
junctions are actively assembling or disassembling [9,64], and
biosensor experiments have confirmed that Rap1 is activated at
sites of cell-cell contact [65]. These observations hint at a fine-
tuning role for Rap1 during situations that require dynamic
junction assembly/disassembly. Resolution of RPE barrier func-
tion in the laser-CNV model would be an example of this.
The junctional linearization we observe in RPE treated with
8CPT-cAMP both in vitro and in vivo likely involves non-muscle
myosin contractility, through regulation of myosin light chain
(MLC) phosphorylation. Many studies have correlated increased
phosphorylation of MLC with junctional disruption, increased
permeability, and actin cytoskeleton reorganization (recently
reviewed in Cunningham et al. [66]. In RPE, thrombin-induced
phosphorylation of MLC increased actin stress fibers in a Rho
kinase and myosin light chain kinase (MLCK)-dependent fashion
[67]. Interestingly, Shen et al. [68] noted that in epithelia with
increased phospho-MLC, cell junctions became ‘‘irregularly
undulating’’ which we would characterize as equivalent to having
decreased linearity. In corneal endothelial cells, elevating cAMP
(which would activate Rap1 in a manner similar to 8CPT-cAMP),
helps preserve barrier function after thrombin treatment [69] and
also results in MLC dephosphorylation [70]. On the other hand,
Nakajima et al. found that junction linearization requires localized
phospho-MLC; in the absence of this, b-catenin localization
becomes discontinuous, and the actin circumferential belt is
attenuated [71]. Future studies will determine the phosphorylation
status of MLC in RPE treated with 8CPT-cAMP to further clarify
the mechanism of junctional linearity.
We interpret our measurement of increased junctional linearity
after 8CPT-cAMP treatment (Fig. 6D) as being indicative of
uniform circumferential junctional tension between adjacent cells.
This is analogous to surface tension-directed packing of soap
bubbles and the physical tendency for surface areas to be
minimized as in the hexagonal organization of Drosophila retinal
cells [72]. Linear geometry, as opposed to a slack or wavy
appearance of epithelial cell boundaries has been correlated with
increased junctional integrity and barrier properties [33,42]. In
Drosophila, mutation of the Rap1 GEF dPDZ-GEF affected cell
shape in wing disc epithelia [73], and more recently, it was shown
that Rap1 activity level within a particular subset of cells
correlated with this process [74]. Rap1 activity was down-
regulated specifically in vein cells, resulting in adhesive asymme-
tries and non-hexagonal morphology, reminiscent of the non-
linear appearance of the cells bordering the lesions of non-8CPT-
cAMP treated RPE in our experiments. This also suggests that the
increased Rap1 activity in RPE cells treated with 8CPT-cAMP
post-laser is playing an important role in directing cell shape
changes that promote cell-cell adhesion and junctional conforma-
tion.
Rap1 GTPase is becoming appreciated for its role in regulating
cell-cell adhesion in both endothelial and epithelial cell systems. In
vitro, using well-accepted models of epithelial barrier integrity, we
show that Rap1A is important in maintaining steady-state RPE
barrier integrity, while Rap1B is involved in resisting disassembly
and promoting reassembly following junction disruption. Using
knockout mouse models, we also provide evidence that Rap1B
plays a role in containing and/or preventing choroidal endothelial
cell invasion across the RPE and into the sensory retina, a step that
is relevant in a number of eye diseases, including choroidal
neovascularization associated with degenerative myopia, central
serous retinopathy and age-related macular degeneration. In fact,
recent computer simulations suggest that impairment of RPE-RPE
adhesion is a major contributor in the transition to vision
threatening sub-retinal CNV [75], perhaps facilitating the
development of sensory retinal CNV by permitting otherwise
restricted entry of growth factors and cells into the sensory retina
from the choroid. This, together with our data showing that Rap1
activation using compounds such as 8CPT-cAMP reduces CEC
migration and CNV suggests that targeting Rap1 may be a
promising pharmacological treatment method for neovascular
AMD and has potential for application to other human diseases
where loss of barrier integrity occurs.
Supporting Information
Figure S1 Rap1 isoform shRNA and antibody specific-
ity. (A) To confirm knockdown specificity, lysates from cultured
RPE expressing negative control, Rap1A, or Rap1B shRNA
adenoviral constructs were probed with isoform-specific antibodies
and b-actin as a loading control. (B) Rap1 isoform antibody
specificity. Total cell lysates of lung tissue obtained from WT,
Rap1a2/2, or Rap1b2/2 mice were run on SDS-PAGE and
Western blotted using antibodies against the Rap1A isoform,
Rap1B isoform, and total Rap1 (1A+1B) as indicated. For each set,
blots were reprobed with anti-b-actin antibodies to confirm equal
protein loading.
(TIF)
Figure S2 Calcium switch: Rap1B shRNA monolayers
are more disrupted and slower to recover following
washout. Cells were plated in parallel and treated with EGTA
for 30 min, followed by washout for 1 or 3 hr as in Fig. 2. Lower
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magnification images show overall monolayer disruption and
larger cell-free gap area.
(TIF)
Figure S3 Intravitreal injection of 8CPT-29O-Me-cAMP
is not toxic. (A) Representative fluorescein angiogram showing
location of sd-OCT retinal thickness measurements (marked by X)
relative to location of retinal vessels and lasered spots (lighter
circular regions). (B) Representative sd-OCT cross-section showing
retinal layers. (RNFL/GC, retinal nerve fiber layer/ganglion cell
layer; IP, inner plexiform layer; IN, inner nuclear layer; OP, outer
plexiform layer; ON, outer nuclear layer; ELM, external limiting
membrane; IS/OS, inner/outer segment of photoreceptors; RPE,
retinal pigment epithelium) Red arrow denotes region of retinal
thickness measurements. (C) Quantification of retinal thickness
using the average measurements from 2–4 regions per sd-OCT
image of n= 18 eyes per condition (PBS vs. 8CPT-29O-Me-cAMP
intravitreal injections). Intravitreal injections of 8CPT-29-O-Me-
cAMP does not increase retinal thickness. (D) Western blot of
RPE-choroid cell lysates 24 hrs following intravitreal injection of
PBS, 8CPT-29-O-Me-cAMP, or staurospaurine-treated H1B-1B
cells as a positive control, using antibodies for caspase-3 and
cleaved-caspase 3. b-actin levels serve as a loading control. (E)
TUNEL staining (green) of cryo-sectioned eyes 24 hrs following
PBS or 8CPT-29-O-Me-cAMP injection. DNase-treatment of
cryosections served as positive control.
(TIF)
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